Pregnancy

Available clinical trial data for VEKLURY in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes following second- and third-trimester exposure. There are insufficient data to evaluate the risk of VEKLURY exposure during the first trimester.

Lactation

The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VEKLURY and any potential adverse effects on the breastfed child from VEKLURY or from an underlying maternal condition

Warnings

Contraindicated: Hypersensitivity ; Warnings: Increased risk of transaminase levels, risk of reduced antiviral activity with use of chloroquine or hydroxychloroquine